Brand Name Drug Negotiations Status
The pCPA is a part of the overall Canadian drug approval and reimbursement process. It starts with regulatory approval through Health Canada where drugs are evaluated for efficacy, quality and safety. Following a positive approval from Health Canada, all drugs then go through a health technology assessment for clinical and cost-effectiveness. In Canada there are two review boards, the Canadian Agency for Drugs and Technologies in Health (CADTH) which reviews common drugs through the Common Drug Review (CDR) and oncology drugs through the Pan-Canadian Oncology Drug Review (pCODR). In Quebec, drugs are reviewed through l’Institut national d’excellence en santé et en services sociaux (INESSS). For the majority of new drugs, the pCPA negotiation process begins once a recommendation is published by CADTH and/or INESSS.
| Product | Manufacturer | Status | Indication |
|---|---|---|---|
| Evenity (romosozumab) | Amgen Canada Inc. | Under consideration for negotiation | osteoporosis |
| MAR-Trientine (trientine) | Amgen Canada Inc. | Under consideration for negotiation | Wilson's Disease |
| Tukysa ( tucatinib) | Seagen Canada Inc. | Under consideration for negotiation | Tucatinib is indicated in combination with trastuzumab and capecitabine for treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received prior treatment with trastuzumab, pertuzumab, and trastuzumab emtansine, separately or in combination |
| Abecma (idecabtagene vicleucel) | Celgene Inc. | Under consideration for negotiation | For the treatment of adult patients with multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and who are refractory to their last treatment |
| Zaxine (rifaximin) | Lupin Pharma Canada Limited | Active Negotiation | Hepatic Encephalopathy |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Under consideration for negotiation | Adult and pediatric patients with refractory or relapsed classical Hodgkin Lymphoma (cHL), as monotherapy, who have failed autologous stem cell transplant (ASCT) or who are not candidates for multi-agent salvage chemotherapy and ASCT |
| Onureg (azacitidine) | Celgene Inc. | Under consideration for negotiation | Maintenance therapy in adult patients with acute myeloid leukemia (AML) who achieved complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following induction therapy with or without consolidation treatment, and who are not eligible for hematopoietic stem cell transplantation (HSCT) |
| Abrilada (adalimumab) | Pfizer Canada ULC | Active Negotiation | Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis |
| Yuflyma (adalimumab) | Celltrion Healthcare Canada Ltd. | Active Negotiation | Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis |
| Givlaari (givosiran) | Alnylam Pharmaceuticals Canada ULC | Under consideration for negotiation | acute hepatic porphyria |
| Xeomin (incobotulinumtoxinA) | Merz Therapeutics Canada | Under consideration for negotiation | chronic sialorrhea associated with neurological disorders |
| Perseris (risperidone) | HLS Therapeutics Inc. | Under consideration for negotiation | Schizophrenia |
| Inqovi (Decitabine-Cedazuridine) | Taiho Pharma Canada, Inc. | Under consideration for negotiation | Inqovi (decitabine and cedazuridine) is indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System (IPSS) groups |
| Saxenda (liraglutide) | Novo Nordisk Canada Inc. | Negotiations were not pursued | chronic weight management |
| Vitrakvi (larotrectinib) | Bayer Inc. | Under consideration for negotiation | For the treatment of adult and pediatric patients with solid tumours that: have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation; are metastatic or where surgical resection is likely to result in severe morbidity, and; have no satisfactory treatment options. |
| Breztri Aerosphere (budesonide/glycopyrronium/ formeterol fumarate dihydrate) | ASTRAZENECA CANADA INC | Under consideration for negotiation | Chronic Obstructive Pulmonary Disease |
| Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) | Vertex Pharmaceuticals (Canada) Incorporated | Concluded with an LOI | Cystic Fibrosis, F508del CFTR mutation |
| Vyxeos (daunorubicin and cytarabine) | Jazz Pharmaceuticals Canada Inc. | Under consideration for negotiation | For the treatment of adults with newly diagnosed therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). |
| Tecartus (brexucabtagene autoleucel) | Gilead Sciences Canada Inc. | Active Negotiation | For the treatment of adult patients with relapsed or refractory (r/r) mantle cell lymphoma (MCL) who have received treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) |
| Evrysdi (risdiplam) | HOFFMANN-LA ROCHE LIMITED | Active Negotiation | Spinal Muscular Atrophy |
| Rinvoq (upadacitinib) | AbbVie Corporation | Under consideration for negotiation | Psoriatic Arthritis |
| Entuzity KwikPen (human insulin) | Eli Lilly Canada Inc. | Active Negotiation | Diabetes Mellitus, Type 1 & 2 |
| Jorveza (budesonide) | AVIR Pharma Inc. | Active Negotiation | eosinophic esophagitis (maintenance) |
| Venclexta (venetoclax) | AbbVie Corporation | Negotiations were not pursued | Venclexta in combination with low-dose cytarabine is indicated for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) who are 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy |
| Venclexta (venetoclax) | AbbVie Corporation | Active Negotiation | in combination with azacitidine for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) who are 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy |
| Entresto (sacubitril/valsartan) | Novartis Pharmaceuticals Canada Inc. | Active Negotiation | Heart failure, NYHA class II or III |
| Opdivo-Yervoy (nivolumab-ipilimumab) | Bristol Myers Squibb Canada Inc. | Active Negotiation | OPDIVO, in combination with ipilimumab, is indicated for the treatment of adult patients with unresectable malignant pleural mesothelioma (MPM) who have not received prior systemic therapy for MPM |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI | For the first line treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) |
| Imfinzi (durvalumab) | AstraZeneca Canada Inc. | Active Negotiation | IMFINZI in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) |
| Braftovi (encorafenib) | PFIZER CANADA ULC. | Active Negotiation | Braftovi in combination with cetuximab, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by a validated test, after prior therapy, |
| Braftovi/Mektovi (encorfenib/binimetinib) | PFIZER CANADA ULC | Active Negotiation | Braftovi (encorafenib) and Mektovi (binimetinib), in combination, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation, as detected by a validated test |
| Unituxin (dinutuximab) | United Therapeutics | Active Negotiation | high-risk neuroblastoma patients in their first relapse or determination of refractory disease, in combination with irinotecan, temozolomide, and granulocyte macrophage colony-stimulating factor |
| Inrebic (fedrantinib) | Celgene Inc. | Under consideration for negotiation | splenomegaly &/or disease-related symptoms in adult patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis, including patients previously exposed to ruxolitinib |
| Zeposia (ozanimod) | Celgene Inc. | Negotiations were not pursued | Relapsing-Remitting Multiple Sclerosis |
| Rybelsus (semaglutide) | Novo Nordisk Canada Inc. | Active Negotiation | Diabetes Mellitus, Type 2 |
| Insulin pumps and pump supplies (Insulin pumps and pump supplies) | Multiple manufacturers | Active Negotiation | Diabetes Mellitus, Type 1 & 2 |
| Veltassa (patiromer) | Otsuka Canada Pharmaceuticals Inc. | Active Negotiation | hyperkalemia |
| Reblozyl (luspatercept) | Celgene Inc. | Under consideration for negotiation | anemia associated with beta-thalassemia |
| Dupixent (dupilumab) | Sanofi Genzyme | Active Negotiation | Asthma |
| Tafinlar/Mekinist (dabrafenib/trametinib) | Novartis Pharmaceuticals Canada Inc. | Active Negotiation | Non-small cell lung cancer: for the treatment of metastatic non-small cell lung cancer (NSCLC) with a BRAF V600 mutation and who have not received any prior anti-cancer therapy for metastatic disease |
| Ilumya (tildrakizumab) | Sun Pharma Canada Inc. | Active Negotiation | Psoriasis, moderate to severe plaque |
| Simlandi (adalimumab) | Jamp Pharma Corporation | Active Negotiation | Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis |
| Corzyna (ranolazine) | KYE Pharmaceuticals | Under consideration for negotiation | Angina pectoris |
| Zejula (Niraparib) | GlaxoSmithKline Inc. | Concluded with an LOI | Ovarian Cancer: Maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy |
| Odomzo (sonidegib) | Sun Pharma Canada Inc. | Negotiations were not pursued | Basal Cell Carcinoma (BCC): For the treatment of adult patients with histologically confirmed laBCC that is not amenable to radiation therapy or curative surgery |
| Bambevi (bevacizumab) | Apotex Inc. | Concluded with an LOI | Metastatic Colorectal Cancer (mCRC) Locally Advanced, Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer Malignant Glioma (WHO Grade IV) - Glioblastoma |
| Polivy (Polatuzumab Vedotin) | HOFFMANN-LA ROCHE LIMITED | Concluded with an LOI | In combo with bendamustine & rituximab is indicated for the treatment of adult patients with relapsed or refractory DLBCL, not otherwise specified, who are not eligible for autologous stem cell transplant & have received at least one prior therapy. |
| Alunbrig (brigatinib) | Takeda Canada Inc. | Active Negotiation | For the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) previously untreated with an ALK inhibitor |
| Lynparza (olaparib) | AstraZeneca Canada Inc. | Active Negotiation | Monotherapy for the treatment of adult patients with mCRPC & deleterious or suspected deleterious germline/somatic mutations in the HRR genes BRCA or ATM who have progressed following prior treatment with a NHA |
| Rozlytrek (Entrectinib) | HOFFMANN-LA ROCHE LIMITED | Concluded with an LOI | ROS1-positive Non-Small Cell Lung Cancer |
| Ruzurgi (Amifampridine) | Médunik Canada Inc. | Active Negotiation | Lambert-Eaton myasthenic syndrome (LEMS) |
| Enspryng (satralizumab) | HOFFMANN-LA ROCHE LTD | Active Negotiation | neuromyelitis optica spectrum disorders (NMOSD) |
| Osnuvo (teriparatide) | AVIR Pharma Inc. | Concluded with an LOI | osteoporosis |
| Sarclisa (Isatuximab) | Sanofi Genzyme | Under consideration for negotiation | Isatuximab in combination with pomalidomide and dexamethasone, for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. |
| Remsima SC (infliximab) | Celltrion Healthcare Canada Ltd. | Active Negotiation | Rheumatoid Arthritis |
| Abevmy (bevacizumab) | BGP Pharma ULC | Concluded with an LOI | Metastatic colorectal cancer (mCRC), locally advanced, metastatic or recurrent non-small cell lung Cancer (NSCLC), platinum-resistant recurrent epithelial ovarian, fallopian tube and primary peritoneal cancer, and glioblastoma |
| Bavencio (avelumab) | EMD Serono a Division of EMD Inc. Canada | Active Negotiation | Urothelial Carcinoma (UC) |
| Ajovy (fremanezumab) | Teva Canada Inc. | Active Negotiation | prevention of migraine in adults |
| Opdivo-Yervoy (nivolumab-ipilimumab) | Bristol Myers Squibb Canada Inc. | Active Negotiation | Nivolumab, in combination with ipilimumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of patients with metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations |
| Entresto (sacubitril/valsartan) | Novartis Pharmaceuticals Canada Inc. | Under consideration for negotiation | Heart failure, NYHA class II or III |
| Calquence (Acalabrutinib) | ASTRAZENECA CANADA INC | Concluded with an LOI | Chronic Lymphocytic Leukemia (CLL) (previously untreated): With or without obinutuzumab, for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL) for whom a fludarabine-based regimen is inappropriate |
| Calquence (Acalabrutinib) | ASTRAZENECA CANADA INC | Concluded with an LOI | Chronic Lymphocytic Leukemia: As monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy. |
| Kynmobi (apomorphine hydrochloride) | Sunovion Pharmaceuticals Canada Inc. | Active Negotiation | Parkinson's Disease |
| Kesimpta (ofatumumab) | Novartis Pharmaceuticals Canada Inc. | Active Negotiation | Relapsing-Remitting Multiple Sclerosis |
| Ofev (nintedanib) | Boehringer Ingelheim (Canada) Ltd. Ltee. | Active Negotiation | Chronic fibrosing interstitial lung diseases |
| Darzalex SC (Daratumumab ) | Janssen Inc. | Active Negotiation | Multiple Myeloma |
| Daurismo (Glasdegib) | PFIZER CANADA ULC | Negotiations were not pursued | Acute Myeloid Leukemia (AML) |
| pdp-levETIRAcetam (levetiracetam) | Pendopharm | Active Negotiation | Epilepsy |
| Zolgensma (onasemnogene abeparvovec) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Spinal Muscular Atrophy |
| Tecentriq and bevacizumab (Atezolizumab & Bevacizumab) | HOFFMANN-LA ROCHE LIMITED | Concluded with an LOI | TECENTRIQ (atezolizumab), in combination with AVASTIN (bevacizumab), for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) who require systemic therapy. |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI | Head and Neck Squamous Cell Carcinoma (HNSCC) |
| Forxiga (dapagliflozin) | AstraZeneca Canada Inc. | Concluded with an LOI | Heart failure, NYHA class II or III |
| Entyvio (SC) (vedolizumab) | Takeda Canada Inc. | Concluded with an LOI | Crohn's disease |
| Venclexta (venetoclax) | AbbVie Corporation | Concluded with an LOI | Venetoclax (VENCLEXTA) in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL) who are fludarabine ineligible |
| Adcetris (brentuximab vedotin) | Seattle Genetics Inc. | Concluded with an LOI | Hodgkin's Lymphoma |
| Adcetris (brentuximab vedotin) | Seattle Genetics Inc. | Concluded with an LOI | Primary Cutaneous Anaplastic Large Cell Lymphoma (or CD30- Expressing Mycosis Fungoides) |
| Spravato (esketamine hydrochloride) | JANSSEN INC | Negotiations were not pursued | Major Depressive Disorder |
| Blincyto (blinatumomab) | Amgen Canada Inc. | Concluded with an LOI | Minimal Residual Disease (MRD)-Positive B-Cell Precursor Acute Lymphoblastic Leukemia (BCP ALL) |
| Riabni (rituximab) | Amgen Canada Inc. | Concluded with an LOI | Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA), Granulomatosis with Polyangitis (GPA), Microscopic Polyangitis (MPA) |
| Inclunox (enoxaparin) | Sandoz Canada Inc. | Concluded with an LOI | Deep vein thrombosis (treatment and prevention) |
| Noromby (enoxaparin) | Juno Pharmaceuticals Corp. | Concluded with an LOI | Deep vein thrombosis (treatment and prevention) |
| Nyvepria (pegfilgrastim) | Pfizer Canada Inc. | Concluded with an LOI | febrile neutropenia in non-myeloid malignancies |
| Trurapi (insulin aspart) | SANOFI-AVENTIS | Concluded with an LOI | Diabetes Mellitus, Type 1 & 2 |
| Foquest (methylphenidate) | Elvium Life Sciences | Concluded with an LOI | Attention-deficit/hyperactivity disorder (ADHD) |
| Suboxone (film) (buprenorphine and naloxone) | Indivior UK Limited | Concluded with an LOI | Opioid drug dependence |
| Atectura Breezhaler (indacaterol /mometasone furoate) | Valeo Pharma Inc. | Concluded with an LOI | Asthma |
| Enerzair Breezhaler (indacaterol/glycopyrronium/mometasone furoate) | Valeo Pharma Inc. | Concluded with an LOI | Asthma |
| Luxturna (voretigene neparvovec) | Novartis Pharmaceuticals Canada Inc. | Active Negotiation | Inherited retinal disease |
| Blood glucose test strips (blood glucose test strips) | Multiple manufacturers | Concluded with an LOI | Diabetes Mellitus, Type 1 & 2 |
| Hadlima (adalimumab) | Merck | Concluded with an LOI | Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis |
| Idacio (adalimumab) | Fresenius Kabi Canada Ltd. | Concluded with an LOI | Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis |
| Hyrimoz (adalimumab) | Sandoz Canada Inc. | Concluded with an LOI | Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis |
| Amgevita (adalimumab) | AMGEN CANADA INC | Concluded with an LOI | Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis |
| Hulio (adalimumab) | BGP Pharma ULC | Concluded with an LOI | Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis |
| Jorveza (budesonide) | AVIR Pharma Inc. | Active Negotiation | Eosinophilic esophagitis |
| Duobrii (Halobetasol propionate and tazarotene) | Bausch Health, Canada Inc. | Concluded with an LOI | Psoriasis, moderate to severe plaque |
| Nexplanon (etonogestrel) | MERCK CANADA INC | Concluded with an LOI | prevention of pregnancy |
| Soliris (eculizumab) | Alexion Pharma GMBH | Active Negotiation | Myasthenia Gravis |
| Zejula (Niraparib) | GlaxoSmithKline Inc. | Concluded with an LOI | Ovarian Cancer: As monotherapy for the maintenance treatment of female adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy |
| Xtandi (enzalutamide) | Astellas Pharma Inc. | Concluded with an LOI | Metastatic Castration Sensitive Prostate Cancer |
| Cablivi (caplacizumab) | SANOFI-AVENTIS | Negotiations were not pursued | acquired thrombotic thrombocytopenic purpura (aTTP) |
| Rituxan SC (rituximab) | Hoffmann-La Roche | Concluded with an LOI | Venetoclax (VENCLEXTA) in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL) who are fludarabine ineligible |
| Tecentriq & Avastin (Atezolizumab & Bevacizumab) | HOFFMANN-LA ROCHE LIMITED | Negotiations were not pursued | Non-Squamous Non-Small Cell Lung Cancer |
| Aimovig (erenumab) | NOVARTIS PHARMACEUTICALS CANADA INC | Active Negotiation | migraine, chronic |
| Vocabria and Cabenuva (cabotegravir and rilpivirine) | VIIV HEALTHCARE ULC | Concluded with an LOI | HIV Infection |
| Mayzent (siponimod) | NOVARTIS PHARMACEUTICALS CANADA INC | Concluded with an LOI | Secondary progressive multiple sclerosis (SPMS) |
| Vascepa (icosapent ethyl) | HLS THERAPEUTICS INC | Active Negotiation | Ischemic events in statin-treated patients |
| Stelara (ustekinumab) | Janssen Inc. | Concluded without agreement | Ulcerative Colitis |
| Soliris (eculizumab) | Alexion Pharma GMBH | Active Negotiation | Neuromyelitis optica spectrum disorder (NMOSD) |
| Darzalex SC (Daratumumab ) | Janssen Inc. | Concluded without agreement | Multiple Myeloma |
| Adcetris (brentuximab vedotin) | Seattle Genetics Inc. | Concluded with an LOI | Peripheral T-Cell Lymphoma |
| Cuvposa (Glycopyrrolate) | Medexus Inc. | Under consideration for negotiation | chronic severe drooling, neurologic (pediatric) |
| Xospata (Gilteritinib) | Astellas Pharma Inc. | Concluded with an LOI | Acute Myeloid Leukemia |
| Aermony Respiclick (fluticasone propionate) | Teva Canada Limited | Concluded with an LOI | Asthma |
| Kisqali (ribociclib) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Advanced or Metastatic Breast Cancer |
| Kalydeco (ivacaftor) | Vertex Pharmaceuticals (Canada) Incorporated | Concluded with an LOI | cystic fibrosis in patients with CFTR gating mutations or the R117H gating mutation |
| Orkambi (lumacaftor/ivacaftor) | Vertex Pharmaceuticals (Canada) Incorporated | Concluded with an LOI | Cystic Fibrosis, F508del CFTR mutation |
| Contrave (naltrexone hydrochloride and bupropion hydrochloride) | Bausch Health, Canada Inc. | Negotiations were not pursued | Chronic weight management |
| Nubeqa (Darolutamide) | Bayer Inc. | Concluded with an LOI | non-metastatic castrate resistant prostate cancer |
| Erleada (apalutamide) | Janssen Inc. | Concluded with an LOI | Metastatic Castration-Sensitive Prostate Cancer |
| Cabometyx (cabozantinib) | Ipsen Biopharmaceuticals | Concluded with an LOI | For the treatment of Hepatocellular Carcinoma (HCC) in adults after prior therapy |
| Crysvita (burosumab) | Ultragenyx Canada Inc. | Concluded with an LOI | X-Linked Hypophosphatemia |
| Entyvio (SC) (vedolizumab) | Takeda Canada Inc. | Concluded with an LOI | Ulcerative Colitis |
| Dupixent (dupilumab) | Sanofi Genzyme | Concluded with an LOI | Atopic dermatitis |
| Beovu (brolucizumab) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Age-Related Macular Degeneration |
| Benlysta (belimumab) | GlaxoSmithKline | Under consideration for negotiation | Systemic lupus erythematosus |
| Kisqali (with fulvestrant) (ribociclib with fulvestrant) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Advanced or Metastatic Breast Cancer |
| Allerject (epinephrine) | Kaleo Inc | Concluded with an LOI | For the emergency treatment of severe acute allergic reactions (anaphylaxis). |
| Otezla (apremilast) | Amgen Canada Inc. | Concluded without agreement | Psoriatic Arthritis |
| Otezla (apremilast) | Amgen Canada Inc. | Concluded without agreement | Psoriasis, moderate to severe plaque |
| Avsola (infliximab) | Amgen Canada Inc. | Concluded with an LOI | Ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn’s disease and Ulcerative Colitis |
| Nivestym (filgrastim) | Pfizer Canada ULC | Concluded with an LOI | Prevention or treatment of neutropenia in various indications |
| Ziextenzo (pegfilgrastim) | Sandoz Canada | Concluded with an LOI | febrile neutropenia in non-myeloid malignancies |
| Redesca (enoxaparin) | Valeo Pharma Inc. | Concluded with an LOI | Deep-Vein Thrombosis (treatment), without Symptomatic Pulmonary Embolism |
| Kanjinti (trastuzumab) | Amgen Canada Inc. | Concluded with an LOI | early breast cancer/metastatic breast cancer/metastatic gastric cancer |
| Envarsus PA (tacrolimus) | Paladin Labs Inc. | Concluded with an LOI | prophylaxis of organ rejection in allogenic kidney or liver transplant adult patients |
| Onstryv (safinamide) | Valeo Pharma Inc. | Under consideration for negotiation | Parkinson's Disease |
| Monoferric (iron (iii) isomaltoside 1000) | Pharmacosmos A/S | Concluded with an LOI | iron deficiency anemia |
| Lokelma (sodium zirconium cyclosilicate) | AstraZeneca Canada Inc. | Negotiations were not pursued | hyperkalemia |
| Taltz (ixekizumab) | Eli Lilly Canada Inc. | Concluded without agreement | Ankylosing spondylitis |
| Vyndaqel (tafamidis) | Pfizer Canada ULC | Concluded with an LOI | transthyretin-mediated amyloidosis |
| Rinvoq (upadacitinib) | AbbVie Corporation | Active Negotiation | Subacute and chronic inflammatory joint diseases |
| Lonsurf (trifluridine/tipiracil) | Taiho Pharma Canada Inc. | Concluded with an LOI | metastatic Gastric Cancer |
| Riximyo (rituximab) | Sandoz Canada | Concluded with an LOI | Rheumatoid arthritis, chronic lymphocytic leukemia, and non-Hodgkin’s lymphoma |
| Ruxience (rituximab) | Pfizer Canada ULC | Concluded with an LOI | Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA), Granulomatosis with Polyangitis (GPA), Microscopic Polyangitis (MPA) |
| Lutathera (lutetium 177 dotatate) | Advanced Accelerator Applications | Concluded with an LOI | Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) |
| Baqsimi (glucagon) | Eli Lilly Canada Inc. | Concluded with an LOI | severe hypoglycemia |
| Admelog (insulin lispro) | Sanofi-aventis Canada Inc. | Concluded with an LOI | Diabetes Mellitus, Type 1 & 2 |
| Lorbrena (lorlatinib) | Pfizer Canada ULC | Negotiations were not pursued | Non-Small Cell Lung Cancer (ALK+) |
| Rydapt (midostaurin) | Novartis Pharmaceuticals Canada Inc. | Negotiations were not pursued | Systemic Mastocytosis |
| Mylotarg (gemtuzumab ozogamicin) | Pfizer Canada ULC | Concluded with an LOI | Acute Myeloid Leukemia |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI | renal cell carcinoma |
| Nerlynx (neratinib) | Knight Therapeutics | Negotiations were not pursued | Hormone Receptor-Positive Breast Cancer |
| Cimzia (certolizumab pegol) | UCB Canada Inc. | Concluded without agreement | Psoriasis, moderate to severe plaque |
| Takhzyro (lanadelumab) | Shire Pharma Canada ULC | Concluded with an LOI | Hereditary Angioedema |
| Revestive (teduglutide) | Shire Pharma Canada ULC | Concluded with an LOI | Short Bowel Syndrome (SBS) |
| Verkazia (cyclosporine) | Santen Incorporated | Concluded with an LOI | severe vernal keratoconjunctivitis |
| Lonsurf (trifluridine/tipiracil) | Taiho Pharma Canada Inc. | Negotiations were not pursued | Metastatic Colorectal Cancer |
| Mezera (mesalazine) | AVIR Pharma Inc. | Concluded with an LOI | Ulcerative Colitis |
| Kadcyla (trastuzumab emtansine) | Hoffmann-La Roche | Concluded with an LOI | early breast cancer |
| Darzalex (daratumumab) | Janssen Inc. | Active Negotiation | Multiple Myeloma |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI | Squamous Non-Small Cell Lung Cancer |
| Tecentriq (atezolizumab) | Hoffmann-La Roche | Active Negotiation | For the treatment of the first-line treatment of patients with extensive stage small cell lung cancer (ES-SCLC) in combination with a platinum-based chemotherapy and etoposide. Maintenance Tecentriq should be continued until loss of clinical benefit or unacceptable toxicity |
| Lynparza (olaparib) | AstraZeneca Canada Inc. | Concluded with an LOI | Ovarian Cancer: As monotherapy for the maintenance treatment of female adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy |
| Trintellix (vortioxetine) | Lundbeck Canada Inc. | Concluded with an LOI | Major Depressive Disorder |
| Xultophy (insulin degludec/liraglutide) | Novo Nordisk Canada Inc. | Concluded without agreement | Diabetes Mellitus, Type 2 |
| Dovato (dolutegravir/lamivudine) | ViiV Healthcare | Concluded with an LOI | HIV Infection |
| Iluvien (fluocinolone acetonide) | Knight Therapeutics | Negotiations were not pursued | Diabetic Macular Edema |
| Emerade (epinephrine bitartrate) | Bausch Health, Canada Inc. | Concluded with an LOI | For the emergency treatment of severe acute allergic reactions (anaphylaxis). |
| Bosulif (bosutinib) | Pfizer Canada ULC | Concluded with an LOI | Chronic Myeloid Leukemia |
| Olumiant (baricitinib) | Eli Lilly Canada Inc. | Concluded with an LOI | Subacute and chronic inflammatory joint diseases |
| Orfadin Oral Suspension (nitisinone) | Sobi Canada Inc. | Concluded without agreement | Hereditary Tyrosinemia Type 1 |
| Onpattro (patisiran) | Alnylam Netherlands B.V. | Concluded with an LOI | hereditary transthyretin-mediated amyloidosis |
| Tegsedi (inotersen) | Akcea Therapeutics Inc. | Concluded with an LOI | hereditary transthyretin-mediated amyloidosis |
| Truxima (rituximab) | Teva Canada Limited | Concluded with an LOI | Rheumatoid arthritis, chronic lymphocytic leukemia, and non-Hodgkin’s lymphoma |
| Vitrakvi (larotrectinib) | Bayer Inc. | Negotiations were not pursued | Neurotrophic Tyrosine Receptor Kinase (NTRK) Locally Advanced or Metastatic Solid Tumours |
| Pomalyst (pomalidomide) | Celgene Inc. | Negotiations were not pursued | Multiple Myeloma (Relapsed) |
| Idhifa (enasidenib) | Celgene Inc. | Under consideration for negotiation | Acute Myeloid Leukemia |
| Revlimid (lenalidomide) | Celgene Inc. | Concluded with an LOI | Multiple Myeloma |
| Sublocade (buprenorphine) | Indivior UK Limited | Concluded with an LOI | Opioid Use Disorder |
| Cystadrops (cysteamine) | Recordati Canada | Concluded with an LOI | corneal cystine crystal deposits |
| Libtayo (cemiplimab) | Sanofi Genzyme | Concluded with an LOI | Cutaneous Squamous Cell Carcinoma |
| Lenvima (lenvatinib) | Eisai Limited | Concluded with an LOI | For the treatment of Hepatocellular Carcinoma (HCC) in adults after prior therapy |
| Darzalex (daratumumab) | Janssen Inc. | Active Negotiation | Multiple Myeloma (newly diagnosed) |
| Lutathera (lutetium 177 dotatate) | Advanced Accelerator Applications | Concluded without agreement | Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) |
| Alunbrig (brigatinib) | Takeda Canada Inc. | Negotiations were not pursued | Non-Squamous Non-Small Cell Lung Cancer |
| Ninlaro (ixazomib) | Takeda Canada Inc. | Negotiations were not pursued | Multiple Myeloma |
| Verzenio (abemaciclib) | Eli Lilly Canada Inc. | Concluded without agreement | Advanced or Metastatic Breast Cancer |
| Vizimpro (dacomitinib) | Pfizer Canada ULC | Concluded without agreement | Non-Squamous Non-Small Cell Lung Cancer |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Negotiations were not pursued | Metastatic Urothelial Carcinoma (first line) |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI | Melanoma adjuvant therapy |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI | Non-Squamous Non-Small Cell Lung Cancer |
| Venclexta/rituximab (venetoclax/rituximab) | AbbVie Corporation | Concluded with an LOI | Venetoclax (VENCLEXTA) in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL) who are fludarabine ineligible |
| Xalkori (crizotinib) | Pfizer Canada ULC | Concluded with an LOI | ROS1-positive advanced Non-Small Cell Lung Cancer |
| Ibrance/fulvestrant (palbociclib/fulvestrant) | Pfizer Canada ULC | Concluded with an LOI | Advanced or Metastatic Breast Cancer |
| Imfinzi (durvalumab) | AstraZeneca Canada Inc. | Concluded with an LOI | Non-small Cell Lung Cancer |
| Tafinlar/Mekinist (dabrafenib/trametinib) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Melanoma adjuvant therapy |
| Trazimera (trastuzumab) | Pfizer Canada ULC | Concluded with an LOI | early breast cancer/metastatic breast cancer/metastatic gastric cancer |
| Herzuma (trastuzumab) | Teva Canada Limited | Concluded with an LOI | early breast cancer/metastatic breast cancer/metastatic gastric cancer |
| Ogivri (trastuzumab) | BGP Pharma ULC | Concluded with an LOI | early breast cancer/metastatic breast cancer/metastatic gastric cancer |
| Opsumit (macitentan) | Actelion Pharmaceuticals Ltd. | Concluded with an LOI | Pulmonary Arterial Hypertension |
| Brilinta (ticagrelor) | AstraZeneca Canada Inc. | Concluded with an LOI | secondary prevention of atherothrombotic events |
| Triamcinolone Hexacetonide (triamcinolone hexacetonide) | Medexus Inc. | Concluded with an LOI | Subacute and chronic inflammatory joint diseases |
| Skyrizi (risankizumab) | AbbVie Corporation | Concluded with an LOI | Plaque psoriasis |
| Vyzulta (latanoprostene bunod) | Bausch Health, Canada Inc. | Concluded with an LOI | Open-angle Glaucoma |
| Blincyto (blinatumomab) | Amgen Canada Inc. | Concluded with an LOI | Philadelphia chromosome positive (Ph+) B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) |
| Folotyn (pralatrexate) | Servier Canada Inc. | Concluded with an LOI | Peripheral T-Cell Lymphoma |
| Botox (onabotulinumtoxin a) | Allergan Inc. | Concluded without agreement | migraine, chronic |
| Xermelo (telotristat) | Ipsen Biopharmaceuticals | Negotiations were not pursued | carcinoid syndorme |
| Jublia (efinaconazole) | Bausch Health, Canada Inc. | Negotiations were not pursued | onychomycosis |
| Pifletro (doravirine) | Merck Canada Inc. | Concluded with an LOI | HIV Infection |
| Delstrigo (doravirine/lamuvidine/tenofovir disoproxil fumarate) | Merck Canada Inc. | Concluded with an LOI | HIV Infection |
| Cresemba (isavuconazole) | AVIR Pharma Inc. | Concluded with an LOI | Treatment of invasive aspergillosis and mucormycosis |
| Unituxin (dinutuximab) | United Therapeutics | Concluded with an LOI | neuroblastoma |
| Xtandi (enzalutamide) | Astellas Pharma Inc. | Concluded with an LOI | non-metastatic castrate resistant prostate cancer |
| Opdivo (nivolumab) | Bristol Myers Squibb Canada Inc. | Concluded with an LOI | Melanoma adjuvant therapy |
| Adcetris (brentuximab vedotin) | Seattle Genetics Inc. | Negotiations were not pursued | Hodgkin's Lymphoma |
| Radicava (edaravone) | Mitsubishi Tanabe Pharma Corporation | Concluded with an LOI | amyotrophic lateral sclerosis |
| Eucrisa (crisaborole) | Pfizer Canada ULC | Negotiations were not pursued | Atopic dermatitis |
| Brineura (cerliponase alfa) | BioMarin Pharmaceutical Inc. | Concluded with an LOI | neuronal ceroid lipofuscinosis type 2 |
| Kalydeco (ivacaftor) | Vertex Pharmaceuticals (Canada) Incorporated | Concluded with an LOI | cystic fibrosis in patients with CFTR gating mutations or the R117H gating mutation |
| Zirabev (bevacizumab) | Pfizer Canada ULC | Concluded with an LOI | Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer |
| Spinraza (nusinersen) | Biogen Canada Inc. | Concluded with an LOI | Spinal Muscular Atrophy |
| Xeljanz (tofacitinib) | Pfizer Canada ULC | Concluded with an LOI | Ulcerative Colitis |
| Cabometyx (cabozantinib) | Ipsen Biopharmaceuticals | Concluded with an LOI | renal cell carcinoma |
| Mvasi (bevacizumab) | Amgen Canada Inc. | Concluded with an LOI | Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer |
| Ella (ulipristal acetate) | Allergan Inc. | Concluded with an LOI | prevention of pregnancy |
| Segluromet (ertugliflozin/metformin hydrochloride) | Merck Canada Inc. | Concluded without agreement | Diabetes Mellitus, Type 2 |
| Steglatro (ertugliflozin) | Merck Canada Inc. | Concluded without agreement | Diabetes Mellitus, Type 2 |
| Fulphila (pegfilgastrim) | BGP Pharma ULC | Concluded with an LOI | febrile neutropenia in non-myeloid malignancies |
| Xeljanz XR (tofacitinib) | Pfizer Canada ULC | Concluded with an LOI | Subacute and chronic inflammatory joint diseases |
| Humira (citrate-free) (adalimumab citrate-free) | AbbVie Corporation | Concluded without agreement | Multiple Indications |
| Ozempic (semaglutide) | Novo Nordisk Canada Inc. | Concluded with an LOI | Diabetes Mellitus, Type 2 |
| Herceptin SC (trastuzumab) | Hoffmann-La Roche | Concluded without agreement | breast cancer |
| Tagrisso (osimertinib) | AstraZeneca Canada Inc. | Concluded with an LOI | first-line treatment of locally advanced or metastatic non-small cell cell lung cancer (NSCLC) |
| Lenvima (lenvatinib) | Eisai Limited | Negotiations were not pursued | advanced or metastatic, clear-cell renal cell carcinoma |
| Harvoni (ledipasvir/sofosbuvir) | Gilead Sciences Canada Inc. | Concluded with an LOI | Chronic Hepatitis C |
| Velphoro (sucroferric oxyhydroxide) | Vifor Fresenius Medical Care Renal Pharma | Concluded with an LOI | Hyperphosphatemia, end-stage renal disease |
| Soliqua (lixisenatide/insulin glargine) | Sanofi-aventis Canada Inc. | Concluded with an LOI | Diabetes Mellitus, Type 2 |
| Perjeta/Herceptin (pertuzumab/trastuzumab) | Hoffmann-La Roche | Negotiations were not pursued | early breast cancer |
| Opdivo (nivolumab) | Bristol Myers Squibb Canada Inc. | Negotiations were not pursued | For the treatment of Hepatocellular Carcinoma (HCC) in adults after prior therapy |
| Daklinza (daclatasvir) | Bristol Myers Squibb Canada Inc. | Concluded with an LOI | Chronic Hepatitis C |
| Januvia (sitagliptin phosphate) | Merck Canada Inc. | Concluded with an LOI | Diabetes Mellitus, Type 2 |
| Yervoy/Opdivo (nivolumab/ipilimumab) | Bristol Myers Squibb Canada Inc. | Concluded with an LOI | renal cell carcinoma |
| Gazyva (obinutuzumab) | Hoffmann-La Roche | Negotiations were not pursued | Follicular Lymphoma |
| Erleada (apalutamide) | Janssen Inc. | Concluded with an LOI | non-metastatic castrate resistant prostate cancer |
| Xarelto (rivaroxaban) | Bayer Inc. | Concluded with an LOI | Prevention of stroke and cardiovascular events in coronary and peripheral artery disease. |
| Ozurdex (dexamethasone) | Allergan Inc. | Negotiations were not pursued | Diabetic Macular Edema |
| Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) | Gilead Sciences Canada Inc. | Concluded with an LOI | HIV infection |
| Fibristal (ulipristal acetate) | Allergan Inc. | Concluded with an LOI |
Intermittent treatment of moderate to severe signs and symptoms of uterine fibroids uterine fibroids |
| Alecensaro (alectinib) | Hoffmann-La Roche | Concluded with an LOI | Non-Small Cell Lung Cancer (First Line) |
| Praluent (alirocumab) | Sanofi-aventis Canada Inc. | Concluded without agreement | Atherosclerotic cardiovascular disease |
| Orkambi (lumacaftor/ivacaftor) | Vertex Pharmaceuticals (Canada) Incorporated | Negotiations were not pursued | Cystic Fibrosis, F508del CFTR mutation |
| Arbesda RespiClick (fluticasone propionate/salmeterol xinafoate) | Teva Canada Limited | Concluded without agreement | Asthma |
| Aermony Respiclick (fluticasone propionate) | Teva Canada Limited | Concluded without agreement | Asthma |
| Viberzi (eluxadoline) | Allergan Inc. | Negotiations were not pursued | Irritable Bowel Syndrome |
| Kanuma (sebelipase alfa) | Alexion Pharma GMBH | Concluded with an LOI | Lysosomal acid lipase deficiency |
| Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) | GlaxoSmithKline | Concluded with an LOI | Chronic Obstructive Pulmonary Disease |
| Mavenclad (cladribine) | EMD Serono a Division of EMD Inc. Canada | Concluded with an LOI | Relapsing-Remitting Multiple Sclerosis |
| Nucynta (tapentadol hydrochloride) | Paladin Labs Inc. | Negotiations were not pursued | Pain, severe |
| Fasenra (benralizumab) | AstraZeneca Canada Inc. | Concluded with an LOI | Eosinophilic Asthma |
| Dysport Therapeutic (abobotulinumtoxina) | Ipsen Biopharmaceuticals | Concluded with an LOI | Lower Limb Spasticity |
| Nitisinone (nitisinone) | Cycle Pharmaceuticals Ltd. | Concluded with an LOI | Hereditary Tyrosinemia Type 1 |
| Taltz (ixekizumab) | Eli Lilly Canada Inc. | Concluded with an LOI | Psoriatic Arthritis |
| Duodopa (levodopa/carbidopa) | AbbVie Corporation | Concluded with an LOI | Parkinson's Disease |
| Probuphine (buprenorphine) | Knight Therapeutics | Concluded with an LOI | Opioid Use Disorder |
| Ozanex (ozenoxacin) | Ferrer Internacional | Negotiations were not pursued | Impetigo |
| Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) | Janssen Inc. | Concluded without agreement | HIV infection |
| Lonsurf (trifluridine/tipiracil) | Taiho Pharma Canada Inc. | Concluded with an LOI | Metastatic Colorectal Cancer |
| Besponsa (inotuzumab ozogamicin) | Pfizer Canada ULC | Concluded with an LOI | Acute Lymphoblastic Leukemia |
| Tecentriq (atezolizumab) | Hoffmann-La Roche | Concluded with an LOI | Non-small Cell Lung Cancer |
| Dupixent (dupilumab) | Sanofi Genzyme | Concluded with an LOI | Atopic dermatitis |
| Lapelga (pegfilgrastrim) | Apobiologix | Concluded with an LOI | Febrile Neutropenia |
| Siliq (brodalumab) | Valeant Canada | Concluded with an LOI | Psoriasis, moderate to severe plaque |
| Prevymis (letermovir) | Merck Canada Inc. | Concluded with an LOI | Cytomegalovirus infection prophylaxis |
| Juluca (dolutegravir/rilpivirine) | ViiV Healthcare | Concluded with an LOI | HIV infection |
| Akynzeo (netupitant/palonosetron) | Purdue Pharma | Concluded with an LOI | Nausea and vomiting (chemotherapy induced) prevention |
| Toujeo (insulin glargine injection) | Sanofi-aventis Canada Inc. | Concluded with an LOI | Diabetes Mellitus, Type 1 & 2 |
| Rituxan SC (rituximab) | Hoffmann-La Roche | Concluded with an LOI | Venetoclax (VENCLEXTA) in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL) who are fludarabine ineligible |
| Kevzara (sarilumab) | Sanofi-aventis Canada Inc. | Concluded with an LOI | Subacute and chronic inflammatory joint diseases |
| Dysport Therapeutic (abobotulinumtoxina) | Ipsen Biopharmaceuticals | Concluded with an LOI | Upper Limb Spasticity |
| Dysport Therapeutic (abobotulinumtoxina) | Ipsen Biopharmaceuticals | Concluded with an LOI | Cervical dystonia |
| Enstilar (calcipotriol/betamethasone) | LEO Pharma Inc. | Concluded with an LOI | Psoriasis, moderate to severe plaque |
| Opdivo (nivolumab) | Bristol Myers Squibb Canada Inc. | Concluded with an LOI | Classic Hodgkin's Lymphoma |
| Kisqali (ribociclib) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Advanced or Metastatic Breast Cancer |
| Lartruvo (olaratumab) | Eli Lilly Canada Inc. | Concluded without agreement | Advanced Soft Tissue Sarcoma |
| Stivarga (regorafenib) | Bayer Inc. | Concluded with an LOI | Unresectable Hepatocellular Carcinoma |
| Alecensaro (alectinib) | Hoffmann-La Roche | Concluded with an LOI | Locally advanced or metastatic non-small cell lung cancer |
| Vectibix (panitumumab) | Amgen Canada Inc. | Negotiations were not pursued | Left Sided Metastatic Colorectal Cancer |
| Bavencio (avelumab) | EMD Serono a Division of EMD Inc. Canada | Concluded with an LOI | Metastatic Merkel Cell Carcinoma |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI | Metastatic Urothelial Carcinoma |
| Venclexta (venetoclax) | AbbVie Corporation | Concluded with an LOI | Venetoclax (VENCLEXTA) in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL) who are fludarabine ineligible |
| Adcetris (brentuximab vedotin) | Seattle Genetics Inc. | Concluded with an LOI | Hodgkin's Lymphoma |
| Ocrevus (ocrelizumab) | Hoffmann-La Roche | Concluded with an LOI | Primary Progressive Multiple Sclerosis |
| MDK-Nitisinone (nitisinone) | MendeliKABS Inc | Concluded with an LOI | Hereditary Tyrosinemia Type 1 |
| Monoprost (latanoprost) | Laboratoires Thea | Concluded without agreement | Glaucoma and Ocular Hypertension |
| Actemra (tocilizumab) | Hoffmann-La Roche | Concluded with an LOI | Giant Cell Arteritis |
| Vemlidy (tenofovir alafenamide) | Gilead Sciences Canada Inc. | Concluded without agreement | Hepatitis B |
| Ilaris (canakinumab) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Systemic juvenile idiopathic arthritis |
| Renflexis (infliximab) | Merck Canada Inc. | Concluded with an LOI | Rheumatic Conditions |
| Izba (travoprost) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Open-angle Glaucoma |
| Rexulti (brexpiprazole) | Otsuka Canada Pharmaceuticals | Concluded with an LOI | Schizophrenia |
| Galafold (migalastat) | Amicus Therapeutics | Concluded with an LOI | Fabry's Disease |
| Fiasp (insulin aspart) | Novo Nordisk Canada Inc. | Concluded without agreement | Diabetes Mellitus, Type 1 & 2 |
| Pomalyst (pomalidomide) | Celgene Inc. | Concluded with an LOI | Multiple Myeloma |
| Mictoryl Pediatric (propiverine hydrochloride) | Duchesnay Inc. | Concluded with an LOI | Overactive bladder |
| Jevtana (cabazitaxel) | Sanofi-aventis Canada Inc. | Concluded with an LOI | Castrate resistant metastatic prostate cancer |
| Rosiver (ivermectin) | Galderma Canada Inc. | Concluded without agreement | Rosacea |
| Rydapt (midostaurin) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Acute Myeloid Leukemia |
| Lynparza (olaparib) | AstraZeneca Canada Inc. | Concluded with an LOI | Ovarian Cancer: As monotherapy for the maintenance treatment of female adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy |
| Tagrisso (osimertinib) | AstraZeneca Canada Inc. | Concluded with an LOI | Non-Squamous Non-Small Cell Lung Cancer |
| Gazyva (obinutuzumab) | Hoffmann-La Roche | Concluded with an LOI | Follicular Lymphoma |
| Orfadin (nitisinone) | Sobi Canada Inc. | Concluded with an LOI | Hereditary Tyrosinemia Type 1 |
| Tremfya (guselkumab) | Janssen Inc. | Concluded without agreement | Psoriasis, moderate to severe plaque |
| Procysbi (cysteamine bitartrate) | Horizon Therapeutics Ireland DAC | Concluded with an LOI | Nephropathic cystinosis |
| Maviret (glecaprevir/pibrentasvir) | AbbVie Corporation | Concluded with an LOI | Chronic Hepatitis C |
| Movapo (apomorphine hydrochloride) | Paladin Labs Inc. | Concluded with an LOI | Parkinson's Disease |
| Vosevi (sofosbuvir/velpatasvir/voxilaprevir) | Gilead Sciences Canada Inc. | Concluded with an LOI | Chronic Hepatitis C |
| Spinraza (nusinersen) | Biogen Canada Inc. | Concluded with an LOI | Spinal Muscular Atrophy |
| Zykadia (ceritinib) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Non-Squamous Non-Small Cell Lung Cancer |
| Viacoram (perindopril arginine/amlodipine) | Servier Canada Inc. | Concluded without agreement | Hypertension |
| Adlyxine (lixisenatide) | Sanofi-aventis Canada Inc. | Concluded with an LOI | Diabetes Mellitus, Type 2 |
| Repatha (evolocumab) | Amgen Canada Inc. | Concluded without agreement | Primary hyperlipidemia and mixed dyslipidemia |
| Ocrevus (ocrelizumab) | Hoffmann-La Roche | Concluded with an LOI | multiple sclerosis, relapsing |
| Tresiba (insulin degludec) | Novo Nordisk Canada Inc. | Concluded with an LOI | Diabetes Mellitus, Type 1 & 2 |
| Stivarga (regorafenib) | Bayer Inc. | Negotiations were not pursued | Metastatic Colorectal Cancer |
| VPRIV (velaglucerase) | Shire Pharma Canada ULC | Concluded with an LOI | Gaucher disease |
| Elelyso (taliglucerase alfa) | Pfizer Canada ULC | Concluded with an LOI | Gaucher disease |
| Cerezyme (imiglucerase) | Sanofi Genzyme Canada | Concluded without agreement | Gaucher disease |
| Kyleena (levonorgestrel) | Bayer Inc. | Concluded with an LOI | Conception Control |
| Invega Trinza (paliperidone palmitate) | Janssen Inc. | Concluded with an LOI | Schizophrenia |
| Strensiq (asfotase alfa) | Alexion Pharma GMBH | Concluded with an LOI | pediatric-onset hypophosphatasia |
| Narcan (naloxone hydrochloride) | Adapt Pharma Operations Limited | Concluded with an LOI | Opioid Overdose |
| Methadose (methadone hydrochloride) | Mallinckrodt Canada ULC | Concluded without agreement | Opioid Dependence |
| Metoject (methotrexate) | Medexus Inc. | Concluded with an LOI | Rheumatic Conditions |
| Copaxone (glatiramer acetate) | Teva Canada Limited | Concluded without agreement | Clinically Isolated Syndrome |
| Botox (onabotulinumtoxin a) | Allergan Inc. | Concluded with an LOI | Multiple Indications |
| Faslodex (fulvestrant) | AstraZeneca Canada Inc. | Concluded without agreement | Locally Advanced or Metastatic Breast Cancer |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI | Classic Hodgkin's Lymphoma |
| Onivyde (irinotecan liposome) | Shire Pharma Canada ULC | Concluded without agreement | Metastatic Pancreatic Cancer |
| Yervoy/Opdivo (nivolumab/ipilimumab) | Bristol Myers Squibb Canada Inc. | Concluded with an LOI | Metastatic Melanoma |
| Glatect (glatiramer acetate) | Pendopharm | Concluded with an LOI | Multiple Sclerosis, relapsing - remitting |
| Cerdelga (eliglustat) | Sanofi Genzyme Canada | Concluded without agreement | Gaucher disease |
| Ocaliva (obeticholic acid) | Intercept Pharma Canada | Concluded with an LOI | Primary biliary cholangitis |
| Caprelsa (vandetanib) | Sanofi Genzyme Canada | Concluded with an LOI | Medullary Thyroid Cancer |
| Erelzi (etanercept) | Sandoz Canada Inc. | Concluded with an LOI | Ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, rheumatoid arthritis |
| Zinbryta (daclizumab beta) | Biogen Canada Inc. | Negotiations were not pursued | Multiple Sclerosis, relapsing |
| Darzalex (daratumumab) | Janssen Inc. | Concluded with an LOI | Multiple Myeloma |
| Lixiana (edoxaban) | Servier Canada Inc. | Concluded with an LOI | Venous thromboembolism, treatment and recurrence prevention |
| Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide) | Gilead Sciences Canada Inc. | Concluded with an LOI | HIV infection |
| Lancora (ivabradine) | Servier Canada Inc. | Concluded with an LOI | Heart failure, NYHA class II or III |
| Fibristal (ulipristal acetate) | Allergan Inc. | Concluded without agreement | Uterine fibroids (signs and symptoms) - 2nd cycle pre-surgery |
| Mictoryl (propiverine hydrochloride) | Duchesnay Inc. | Concluded without agreement | Overactive bladder |
| Kevzara (sarilumab) | Sanofi-aventis Canada Inc. | Concluded without agreement | Subacute and chronic inflammatory joint diseases |
| Blincyto (blinatumomab) | Amgen Canada Inc. | Concluded with an LOI | Acute Lymphoblastic Leukemia |
| Actikerall (fluorouracil/salicylic acid) | Cipher | Concluded with an LOI | Hyperkeratotic actinic keratosis |
| Stelara (ustekinumab) | Janssen Inc. | Concluded without agreement | Crohn's disease |
| Lixiana (edoxaban) | Servier Canada Inc. | Concluded with an LOI | Non-valvular atrial fibrillation, prevention of stroke and systemic embolism |
| Blincyto (blinatumomab) | Amgen Canada Inc. | Concluded with an LOI | Pediatric Acute Lymphoblastic Leukemia (ALL) |
| Ravicti (glycerol phenylbutyrate) | Horizon Therapeutics Ireland DAC | Concluded with an LOI | Urea cycle disorders |
| Hemangiol (propranolol oral solution) | Pierre Fabre | Concluded with an LOI | Infantile hemangioma |
| Brivlera (brivaracetam) | UCB Canada Inc. | Concluded with an LOI | Epilepsy, partial-onset seizures |
| Ibrance (palbociclib) | Pfizer Canada ULC | Concluded with an LOI | Advanced Breast Cancer |
| Quinsair (levofloxacin) | Raptor Pharmaceuticals Inc. | Concluded with an LOI | Cystic fibrosis with chronic pulmonary Pseudomonas aeruginosa infections |
| Rituxan (rituximab) | Hoffmann-La Roche | Negotiations were not pursued | Acute Lymphoblastic Leukemia |
| Kyprolis (carfilzomib) | Amgen Canada Inc. | Concluded with an LOI | Multiple Myeloma |
| Uptravi (selexipag) | Actelion Pharmaceuticals Ltd. | Concluded with an LOI | Pulmonary Arterial Hypertension |
| Synjardy (empagliflozin/metformin) | Boehringer Ingelheim (Canada) Ltd. Ltee. | Concluded with an LOI | Diabetes Mellitus, Type 2 |
| Taltz (ixekizumab) | Eli Lilly Canada Inc. | Concluded with an LOI | Psoriasis, moderate to severe plaque |
| Kuvan (sapropterin dihydrochloride) | BioMarin Pharmaceutical Inc. | Concluded with an LOI | Phenylketonuria |
| Jardiance (empagliflozin) | Boehringer Ingelheim (Canada) Ltd. Ltee. | Concluded with an LOI | Diabetes Mellitus, Type 2 with high cardiovascular risk |
| Invokamet (canagliflozin/metformin hydrochloride) | Janssen Inc. | Concluded without agreement | Diabetes Mellitus, Type 2 |
| Brilinta (ticagrelor) | AstraZeneca Canada Inc. | Concluded without agreement | Prevention of atherothrombotic events with history of myocardial infarction |
| Descovy (emtricitabine/tenofovir alafenamide) | Gilead Sciences Canada Inc. | Concluded without agreement | HIV infection |
| Cosentyx (secukinumab) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Ankylosing spondylitis |
| Cosentyx (secukinumab) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Psoriatic Arthritis |
| Revestive (teduglutide) | Shire Pharma Canada ULC | Concluded with an LOI | Short Bowel Syndrome (SBS) |
| Praluent (alirocumab) | Sanofi-aventis Canada Inc. | Concluded with an LOI | Primary hypercholesterolemia (non-familial and heterozygous familial) |
| Kyprolis (carfilzomib) | Amgen Canada Inc. | Concluded with an LOI | Multiple Myeloma |
| Trulicity (dulaglutide) | Eli Lilly Canada Inc. | Concluded without agreement | Diabetes Mellitus, Type 2 |
| Nucala (mepolizumab) | GlaxoSmithKline | Concluded with an LOI | Severe Eosinophilic Asthma |
| Vimizim (elosulfase alfa) | BioMarin Pharmaceutical Inc. | Concluded with an LOI | Mucopolysaccharidosis IVA (Morquio A syndrome) |
| Xolair (omalizumab) | Novartis Pharmaceuticals Canada Inc. | Concluded without agreement | Severe Persistent Asthma |
| Fycompa (perampanel) | Eisai Limited | Concluded with an LOI | Epilepsy, primary generalized tonic-clonic seizures |
| Pheburane (sodium phenylbutyrate) | Médunik | Concluded with an LOI | Urea cycle disorders |
| Naglazyme (galsulfase) | BioMarin Pharmaceutical Inc. | Negotiations were not pursued | Mucopolysaccharidosis VI |
| Repatha (evolocumab) | Amgen Canada Inc. | Concluded with an LOI | Primary hyperlipidemia and mixed dyslipidemia |
| Prolia (denosumab) | Amgen Canada Inc. | Concluded with an LOI | Osteoporosis in Men |
| Kalydeco (ivacaftor) | Vertex Pharmaceuticals (Canada) Incorporated | Concluded without agreement | Cystic Fibrosis (CFTR gating mutations) |
| Truvada (emtricitabine/tenofovir disoproxil fumarate) | Gilead Sciences Canada Inc. | Negotiations were not pursued | HIV infection, pre-exposure prophylaxis |
| Strensiq (asfotase alfa) | Alexion Pharma GMBH | Concluded without agreement | pediatric-onset hypophosphatasia |
| Tafinlar/Mekinist (dabrafenib/trametinib) | Novartis Pharmaceuticals Canada Inc. | Negotiations were not pursued | Non-Small Cell Lung Cancer (with CNS metastases) |
| Giotrif (afatinib) | Boehringer Ingelheim (Canada) Ltd. Ltee. | Concluded with an LOI | Advanced Non Small Cell Lung Cancer |
| Opdivo (nivolumab) | Bristol Myers Squibb Canada Inc. | Concluded with an LOI | Squamos Cell Carcinoma of the Head and Neck |
| Simponi IV (golimumab) | Janssen Inc. | Concluded without agreement | Subacute and chronic inflammatory joint diseases |
| Stivarga (regorafenib) | Bayer Inc. | Concluded with an LOI | Gastrointestinal Stromal Tumours |
| Basaglar (insulin glargine) | Eli Lilly Canada Inc. | Concluded with an LOI | Diabetes Mellitus, Type 1 & 2 |
| Mifegymiso (mifepristone and misoprostol) | Celopharma | Concluded with an LOI | Medical termination of pregnancy |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI | Non-small Cell Lung Cancer |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI | Non-small Cell Lung Cancer |
| Neupro (rotigotine) | UCB Canada Inc. | Concluded with an LOI | Parkinson's Disease |
| Brenzys (etanercept) | Merck Canada Inc. | Concluded with an LOI | Rheumatoid Arthritis and Ankylosing Spondylitis |
| Afinitor (everolimus) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Neuroendocrine tumours of Gastrointestinal or Lung origin |
| XigDuo (dapagliflozin/metformin hydrochloride) | AstraZeneca Canada Inc. | Concluded with an LOI | Diabetes Mellitus, Type 2 |
| Humira (adalimumab) | AbbVie Corporation | Concluded with an LOI | Ulcerative Colitis |
| Avastin (bevacizumab) | Hoffmann-La Roche | Concluded with an LOI | Platinum-Resistant Ovarian Cancer |
| Avastin (bevacizumab) | Hoffmann-La Roche | Concluded with an LOI | Metastatic Colorectal Cancer |
| Sublinox (zolpidem tartrate) | Valeant Canada | Negotiations were not pursued | Insomnia, short-term treatment |
| Ninlaro (ixazomib) | Takeda Canada Inc. | Negotiations were not pursued | Multiple Myeloma |
| Eylea (aflibercept) | Bayer Inc. | Concluded with an LOI | Macular edema secondary to branch retinal vein occlusion |
| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) | Gilead Sciences Canada Inc. | Concluded with an LOI | HIV infection |
| Entresto (sacubitril/valsartan) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Heart failure, NYHA class II or III |
| Entyvio (vedolizumab) | Takeda Canada Inc. | Concluded with an LOI | Crohn's disease |
| Entyvio (vedolizumab) | Takeda Canada Inc. | Concluded with an LOI | Ulcerative Colitis |
| Epclusa (sofosbuvir/velpatasvir) | Gilead Sciences Canada Inc. | Concluded with an LOI | Chronic Hepatitis C |
| Sunvepra (asunaprevir) | Bristol Myers Squibb Canada Inc. | Concluded with an LOI | Chronic Hepatitis C |
| Zepatier (elbasvir/grazoprevir) | Merck Canada Inc. | Concluded with an LOI | Chronic Hepatitis C |
| Otezla (apremilast) | Celgene Inc. | Concluded without agreement | Psoriatic Arthritis |
| Plegridy (peginterferon beta-1a) | Biogen Canada Inc. | Concluded with an LOI | Multiple Sclerosis, relapsing |
| Opsumit (macitentan) | Actelion Pharmaceuticals Ltd. | Concluded without agreement | Pulmonary Arterial Hypertension |
| Caprelsa (vandetanib) | Sanofi Genzyme Canada | Concluded without agreement | Medullary Thyroid Cancer |
| Jakavi (ruxolintib) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Polycythemia vera |
| Alecensaro (alectinib) | Hoffmann-La Roche | Negotiations were not pursued | Non-Small Cell Lung Cancer (with CNS metastases) |
| Stelara (ustekinumab) | Janssen Inc. | Negotiations were not pursued | Psoriatic Arthritis |
| Votrient (pazopanib hydrochloride) | GlaxoSmithKline | Concluded with an LOI | Metastatic Renal Cell Carcinoma |
| Signifor (pasireotide diaspartate) | Novartis Pharmaceuticals Canada Inc. | Negotiations were not pursued | Cushing's disease |
| Samsca (tolvaptan) | Otsuka Canada Pharmaceuticals | Negotiations were not pursued | Hyponatremia, non-hypovolemic |
| Imbruvica (ibrutinib) | Janssen Inc. | Concluded with an LOI | Chronic Lymphocytic Leukemia: As monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy. |
| Grastofil (filgrastim) | ApoPharm Inc. | Concluded with an LOI | Prevention or treatment of neutropenia in various indications |
| Xolair (omalizumab) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Chronic Idiopathic Urticaria |
| Imbruvica (ibrutinib) | Janssen Inc. | Concluded with an LOI | Mantle Cell Lymphoma |
| Lenvima (lenvatinib) | Eisai Limited | Concluded with an LOI | Differentiated Thyroid Cancer |
| Mozobil (plerixafor) | Sanofi-aventis Canada Inc. | Concluded with an LOI | Non-Hodgkin's Lymphoma and Multiple Myeloma |
| Rituxan SC (rituximab) | Hoffmann-La Roche | Concluded with an LOI | ALL for ritux sub-cu |
| Otezla (apremilast) | Celgene Inc. | Concluded without agreement | Psoriasis, moderate to severe plaque |
| Forxiga (dapagliflozin) | AstraZeneca Canada Inc. | Concluded with an LOI | Diabetes Mellitus, Type 2 |
| Vectibix (panitumumab) | Amgen Canada Inc. | Concluded with an LOI | Metastatic Colorectal Cancer |
| Cotellic (cobimetinib) | Hoffmann-La Roche | Concluded with an LOI | Metastatic Melanoma |
| Esbriet (pirfenidone) | Hoffmann-La Roche | Concluded with an LOI | Pulmonary fibrosis (idiopathic, mild to moderate) |
| Ferriprox (deferiprone) | ApoPharm Inc. | Concluded with an LOI | Transfusional iron overload |
| Ofev (nintedanib) | Boehringer Ingelheim (Canada) Ltd. Ltee. | Concluded with an LOI | Idiopathic pulmonary fibrosis (IPF) |
| Simponi SC (golimumab) | Janssen Inc. | Concluded with an LOI | Ulcerative Colitis |
| Arnuity Ellipta (fluticasone furoate) | GlaxoSmithKline | Concluded with an LOI | Asthma |
| Breo Ellipta (fluticasone furoate/vilanterol) | GlaxoSmithKline | Concluded with an LOI | Asthma |
| Opdivo (nivolumab) | Bristol Myers Squibb Canada Inc. | Concluded with an LOI | Metastatic Renal Cell Carcinoma |
| Cosentyx (secukinumab) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Psoriasis, moderate to severe plaque |
| Opdivo (nivolumab) | Bristol Myers Squibb Canada Inc. | Concluded with an LOI | Non-small Cell Lung Cancer |
| Opdivo (nivolumab) | Bristol Myers Squibb Canada Inc. | Concluded with an LOI | Metastatic Melanoma |
| Lemtrada (alemtuzumab) | Sanofi Genzyme Canada | Concluded with an LOI | Relapsing-Remitting Multiple Sclerosis |
| Xeljanz (tofacitinib) | Pfizer Canada ULC | Concluded with an LOI | Subacute and chronic inflammatory joint diseases |
| Daklinza (daclatasvir) | Bristol Myers Squibb Canada Inc. | Concluded without agreement | Chronic Hepatitis C |
| Zydelig (idelalisib) | Gilead Sciences Canada Inc. | Negotiations were not pursued | Follicular Lymphoma |
| Jardiance (empagliflozin) | Boehringer Ingelheim (Canada) Ltd. Ltee. | Concluded with an LOI | Diabetes Mellitus, Type 2 with high cardiovascular risk |
| Trajenta/Jentaduo (linagliptin (linagliptin/metformin)) | Boehringer Ingelheim (Canada) Ltd. Ltee. | Concluded with an LOI | Diabetes Mellitus, Type 2 |
| Nesina (alogliptin) | Takeda Canada Inc. | Negotiations were not pursued | Diabetes Mellitus, Type 2 |
| Prezcobix (darunavir/cobicistat) | Janssen Inc. | Concluded with an LOI | HIV Infection |
| Inspiolto Respimat (tiotropium/olodaterol) | Boehringer Ingelheim (Canada) Ltd. Ltee. | Concluded with an LOI | Heart failure, NYHA class II |
| Spiriva Respimat (tiotropium bromide) | Boehringer Ingelheim (Canada) Ltd. Ltee. | Concluded with an LOI | Chronic Obstructive Pulmonary Disease |
| Byetta (exenatide) | AstraZeneca Canada Inc. | Concluded without agreement | Diabetes Mellitus, Type 2 |
| Blincyto (blinatumomab) | Amgen Canada Inc. | Concluded with an LOI | Acute Lymphoblastic Leukemia |
| Januvia (sitagliptin phosphate) | Merck Canada Inc. | Concluded with an LOI | Diabetes Mellitus, Type 2 |
| Janumet (sitagliptin phosphate) | Merck Canada Inc. | Concluded with an LOI | Diabetes Mellitus, Type 2 |
| Kazano (alogliptin/metformin) | Takeda Canada Inc. | Negotiations were not pursued | Diabetes Mellitus, Type 2 |
| Cimzia (certolizumab pegol) | UCB Canada Inc. | Concluded with an LOI | Ankylosing spondylitis |
| Butrans (buprenorphine) | Purdue Pharma | Concluded without agreement | Pain, persistent (moderate intensity) |
| Actemra SC (tocilizumab) | Hoffmann-La Roche | Concluded with an LOI | Subacute and chronic inflammatory joint diseases |
| Incruse Ellipta (umeclidinium) | GlaxoSmithKline | Concluded with an LOI | Chronic Obstructive Pulmonary Disease |
| Duaklir Genuair (aclidinium bromide/formoterol fumarate dihydrate) | AstraZeneca Canada Inc. | Concluded with an LOI | Chronic Obstructive Pulmonary Disease |
| Inflectra (infliximab) | Hospira Healthcare Corporation | Concluded with an LOI | Ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis |
| Jinarc (tolvaptan) | Otsuka Canada Pharmaceuticals | Negotiations were not pursued | Autosomal dominant polycystic kidney disease (ADPKD) |
| Imbruvica (ibrutinib) | Janssen Inc. | Negotiations were not pursued | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
| Darzalex (daratumumab) | Janssen Inc. | Negotiations were not pursued | Multiple Myeloma |
| Intuniv XR (guanfacine hydrochloride) | Shire Pharma Canada ULC | Negotiations were not pursued | Attention-deficit/hyperactivity disorder (ADHD) |
| Aptiom (eslicarbazepine acetate) | Sunovion Pharmaceuticals Canada Inc. | Concluded with an LOI | Epilepsy, partial-onset seizures |
| Simbrinza (brinzolamide/brimonidine) | Alcon | Concluded with an LOI | Glaucoma and Ocular Hypertension |
| Humira (adalimumab) | AbbVie Corporation | Negotiations were not pursued | Hidradenitis Suppurativa |
| Cyramza (ramucirumab) | Eli Lilly Canada Inc. | Concluded with an LOI | Advanced or Metastatic Gastric Cancer or Gastro-esophageal Junction (GEJ) Adenocarcinoma |
| Eliquis (apixaban) | Bristol Myers Squibb Canada Inc. | Concluded with an LOI | Thromboembolic events (venous), treatment and prevention of recurrence |
| Holkira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) | AbbVie Corporation | Concluded with an LOI | Chronic Hepatitis C |
| Abilify Maintena (aripiprazole) | Otsuka Canada Pharmaceuticals | Concluded with an LOI | Schizophrenia |
| Grastek (phleum pratense) | Merck Canada Inc. | Negotiations were not pursued | Allergy |
| Yondelis (trabectedin) | Janssen Inc. | Negotiations were not pursued | Metastatic Liposarcoma or Leiomyosarcoma |
| Fentora (fentanyl buccal) | Teva Canada Limited | Negotiations were not pursued | Pain (breakthrough), cancer (adults) |
| Fampyra (fampridine) | Biogen Canada Inc. | Negotiations were not pursued | Multiple Sclerosis, improve walking disability |
| Sylvant (siltuximab) | Janssen Inc. | Concluded with an LOI | Multicentric Castleman's Disease (MCD) |
| Anoro Ellipta (umeclidinium/vilanterol) | GlaxoSmithKline | Concluded with an LOI | Chronic Obstructive Pulmonary Disease |
| Revlimid (lenalidomide) | Celgene Inc. | Concluded with an LOI | Multiple Myeloma (newly diagnosed) |
| Rebif (interferon beta-1a) | EMD Serono a Division of EMD Inc. Canada | Concluded with an LOI | Clinically Isolated Syndrome |
| Ultibro Breezhaler (indacaterol/glycopyrronium) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Chronic Obstructive Pulmonary Disease |
| Myrbetriq (mirabegron) | Astellas Pharma Inc. | Concluded with an LOI | Overactive Bladder |
| Tivicay (dolutegravir) | ViiV Healthcare | Concluded with an LOI | HIV Infection |
| Inspra (eplerenone) | Pfizer Canada ULC | Concluded with an LOI | Post myocardial infarction |
| Iclusig (ponatinib) | Paladin Labs Inc. | Concluded with an LOI | Chronic Myeloid Leukemia/Acute Lymphoblastic Leukemia |
| Sovaldi (sofosbuvir) | Gilead Sciences Canada Inc. | Concluded with an LOI | Chronic Hepatitis C |
| Breo Ellipta (fluticasone furoate/vilanterol) | GlaxoSmithKline | Concluded with an LOI | Chronic Obstructive Pulmonary Disease |
| Egrifta (tesamorelin) | Theratechnologies Inc. | Negotiations were not pursued | Lipodystrophy, HIV-infected patients |
| Edarbyclor (azilsartan medoxomil/chlorthalidone) | Takeda Canada Inc. | Negotiations were not pursued | Hypertension |
| Zydelig (idelalisib) | Gilead Sciences Canada Inc. | Concluded with an LOI | Chronic Lymphocytic Leukemia: As monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy. |
| Edarbi (azilsartan medoxomil) | Takeda Canada Inc. | Negotiations were not pursued | Hypertension |
| Dymista (azelastine/fluticasone propionate) | Meda Pharmaceuticals | Negotiations were not pursued | Seasonal allergic rhinitis |
| Tafinlar/Mekinist (dabrafenib/trametinib) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Metastatic Melanoma |
| Cortiment (budesonide) | Ferring | Negotiations were not pursued | Ulcerative Colitis |
| Jetrea (ocriplasmin) | Alcon | Concluded with an LOI | Vitreomacular Adhesion |
| Constella (linaclotide) | Forest Laboratories Canada | Negotiations were not pursued | Irritable bowel syndrome with constipation |
| Xarelto (rivaroxaban) | Bayer Inc. | Concluded with an LOI | Thromboembolic events (venous), pulmonary embolism |
| Keytruda (pembrolizumab) | Merck Canada Inc. | Concluded with an LOI | Metastatic Melanoma |
| Zykadia (ceritinib) | Novartis Pharmaceuticals Canada Inc. | Negotiations were not pursued | Non-Small Cell Lung Cancer (metastatic) |
| Bosulif (bosutinib) | Pfizer Canada ULC | Concluded with an LOI | Chronic Myeloid Leukemia |
| Bystolic (nebivolol) | Allergan Inc. | Negotiations were not pursued | Hypertension |
| Avastin (bevacizumab) | Hoffmann-La Roche | Concluded with an LOI | Cervical Cancer |
| Xalkori (crizotinib) | Pfizer Canada ULC | Concluded with an LOI | Non-Small Cell Lung Cancer (First Line) |
| Istodax (romidepsin) | Celgene Inc. | Concluded with an LOI | Peripheral T-Cell Lymphoma |
| Perjeta (Perjeta/Herceptin) (pertuzumab) | Hoffmann-La Roche | Negotiations were not pursued | Neoadjuvant Breast Cancer |
| Apprilon (doxycycline monohydrate) | Galderma Canada Inc. | Negotiations were not pursued | Rosacea |
| Nexavar (sorafenib) | Bayer Inc. | Negotiations were not pursued | Metastatic Progressive Differentiated Thyroid Carcinoma |
| Aloxi IV (palonosetron hydrochloride) | Eisai Limited | Negotiations were not pursued | Nausea and vomiting (chemotherapy induced) prevention |
| Aloxi (palonosetron hydrochloride) | Eisai Limited | Negotiations were not pursued | Nausea and vomiting (chemotherapy induced) prevention |
| Xtandi (enzalutamide) | Astellas Pharma Inc. | Concluded with an LOI | Metastatic Castration Resistant Prostate Cancer |
| Afinitor (everolimus) | Novartis Pharmaceuticals Canada Inc. | Negotiations were not pursued | Subependymal giant cell astrocytoma associated with tuberous sclerosis complex |
| Imbruvica (ibrutinib) | Janssen Inc. | Concluded with an LOI | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
| Gazyva (obinutuzumab) | Hoffmann-La Roche | Concluded with an LOI | Chronic Lymphocytic Leukemia: As monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy. |
| Abraxane (nab-paclitaxel) | Celgene Inc. | Concluded with an LOI | Metastatic Pancreatic Cancer |
| Yervoy (ipilimumab) | Bristol Myers Squibb Canada Inc. | Concluded with an LOI | First Line Advanced Melanoma |
| Arzerra (ofatumumab) | GlaxoSmithKline | Negotiations were not pursued | Chronic Lymphocytic Leukemia: As monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy. |
| Afinitor (everolimus) | Novartis Pharmaceuticals Canada Inc. | Negotiations were not pursued | renal angiomyolipoma associated with tuberous sclerosis complex (TSC) |
| Adempas (riociguat) | Bayer Inc. | Negotiations were not pursued | Pulmonary Arterial Hypertension (WHO group 1) |
| Abilify (aripiprazole) | Bristol Myers Squibb Canada Inc. | Negotiations were not pursued | Major Depressive Disorder |
| Pomalyst (pomalidomide) | Celgene Inc. | Concluded with an LOI | Multiple Myeloma |
| Zaltrap (aflibercept) | Regeneron | Negotiations were not pursued | Metastatic Colorectal Cancer |
| Effient (prasugrel) | Eli Lilly Canada Inc. | Concluded with an LOI | Acute Coronary Syndrome |
| Seebri (glycopyrronium bromide) | Novartis Pharmaceuticals Canada Inc. | Concluded with an LOI | Chronic Obstructive Pulmonary Disease |
| Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) | Gilead Sciences Canada Inc. | Concluded with an LOI | HIV infection |
| Stivarga (regorafenib) | Bayer Inc. | Concluded with an LOI | Gastrointestinal Stromal Tumours |